Tizona Therapeutics Overview
- Year Founded
-
2014
- Status
-
Private
- Employees
-
46
- Latest Deal Type
-
2ndary - Private
- Investors
-
11
Tizona Therapeutics General Information
Description
Operator of an immunology company intended to harness the power of the immune system to develop treatments for cancer and autoimmune diseases. The company's treatments are designed to modulate the activity of immunosuppressive cells by targeting the cell types and biological mechanisms responsible for immune suppression in the tumor microenvironment, enabling patients to get complete and durable remissions for cancer and autoimmune diseases.
Contact Information
Website
www.tizonatx.comCorporate Office
- 611 Gateway Boulevard
- Suite 221
- San Francisco, CA 94080
- United States
Corporate Office
- 611 Gateway Boulevard
- Suite 221
- San Francisco, CA 94080
- United States
Tizona Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 9. Secondary Transaction - Private | Completed | Clinical Trials - Phase 1 | ||||
| 8. Later Stage VC | 21-Jul-2020 | Completed | Clinical Trials - Phase 1 | |||
| 7. Later Stage VC (Series B3) | 10-Jan-2019 | Completed | Clinical Trials - Phase 1 | |||
| 6. Later Stage VC | 03-Jan-2019 | Completed | Clinical Trials - Phase 1 | |||
| 5. Debt - General | 06-Sep-2018 | Completed | Pre-Clinical Trials | |||
| 4. Early Stage VC (Series B2) | 04-Aug-2017 | Completed | Pre-Clinical Trials | |||
| 3. Early Stage VC (Series B) | 23-Feb-2016 | Completed | Pre-Clinical Trials | |||
| 2. Early Stage VC (Series A) | 17-Sep-2015 | $27M | $27M | Completed | Startup | |
| 1. Accelerator/Incubator | 31-Jul-2015 | Completed | Startup |
Tizona Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B3 | ||||||||
| Series B2 | ||||||||
| Series B | 13,333,332 | $0.000100 | $0.01 | $1.5 | $1.5 | 1x | $1.5 | 13.33% |
| Series A | 27,217,500 | $0.000100 | $0.08 | $1 | $1 | 1x | $1 | 27.22% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Tizona Therapeutics Comparisons
Industry
Financing
Details
Tizona Therapeutics Competitors (54)
One of Tizona Therapeutics’s 54 competitors is Sernova, a Corporation company based in London, Canada.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Sernova | Corporation | London, Canada | ||||
| Aro Biotherapeutics | Venture Capital-Backed | Philadelphia, PA | ||||
| NexImmune | Formerly VC-backed | Gaithersburg, MD | ||||
| Senti Bio | Formerly VC-backed | South San Francisco, CA | ||||
| Adimab | Venture Capital-Backed | Lebanon, NH |
Tizona Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Tizona Therapeutics Patents
Tizona Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2023250952-A1 | Combination therapy involving anti-hla-g antibodies and anti-egfr antibodies, anti-pd1 or anti-pd-l1 antibodies, and/or anti-cd47 | Pending | 08-Apr-2022 | ||
| EP-4504345-A1 | Combination therapy involving anti-hla-g antibodies and anti-egfr antibodies, anti-pd1 or anti-pd-l1 antibodies, and/or anti-cd47 | Pending | 08-Apr-2022 | ||
| AU-2021286650-A1 | Bispecific immune cell engagers with binding specificity for hla-g and another antigen | Inactive | 11-Jun-2020 | ||
| CA-3180883-A1 | Bispecific immune cell engagers with binding specificity for hla-g and another antigen | Pending | 11-Jun-2020 | ||
| EP-4165081-A2 | Bispecific immune cell engagers with binding specificity for hla-g and another antigen | Pending | 11-Jun-2020 | C07K16/2833 |
Tizona Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Tizona Therapeutics Investors (11)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| AbbVie Ventures | Corporate Venture Capital | Minority | ||
| Gilead Sciences | Corporation | Minority | ||
| AbbVie | Corporation | Minority | ||
| InterWest Partners | Venture Capital | Minority | ||
| Abingworth | Venture Capital | Minority |
Tizona Therapeutics FAQs
-
When was Tizona Therapeutics founded?
Tizona Therapeutics was founded in 2014.
-
Where is Tizona Therapeutics headquartered?
Tizona Therapeutics is headquartered in San Francisco, CA.
-
What is the size of Tizona Therapeutics?
Tizona Therapeutics has 46 total employees.
-
What industry is Tizona Therapeutics in?
Tizona Therapeutics’s primary industry is Drug Discovery.
-
Is Tizona Therapeutics a private or public company?
Tizona Therapeutics is a Private company.
-
What is Tizona Therapeutics’s current revenue?
The current revenue for Tizona Therapeutics is .
-
How much funding has Tizona Therapeutics raised over time?
Tizona Therapeutics has raised $520M.
-
Who are Tizona Therapeutics’s investors?
AbbVie Ventures, Gilead Sciences, AbbVie, InterWest Partners, and Abingworth are 5 of 11 investors who have invested in Tizona Therapeutics.
-
Who are Tizona Therapeutics’s competitors?
Sernova, Aro Biotherapeutics, NexImmune, Senti Bio, and Adimab are some of the 54 competitors of Tizona Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
